Synapsinostat, also known as CN13, is a histone deacetylase (HDAC) inhibitor and possible cognitive enhancer. It potently inhibits the class I HDAC1, HDAC2, and HDAC3, with values of 39nM, 41nM, and 100nM, respectively, whereas other HDACs were not assessed. The drug has been found to potently promote synaptogenesis in vitro. Synapsinostat was first described in the scientific literature by 2009. Subsequently, other improved analogues acting as HDAC inhibitors such as crebinostat and neurinostat, which show much greater potency, were described.
See also Histone deacetylase inhibitor Crebinostat Neurinostat Vorinostat
References